BioSpace News Archive

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it will be showcasing new transplant data at the upcoming 21st Annual American Society of Transplant Surgeons (ASTS) Digital Winter Symposium. CareDx is sponsoring two symposia with key clinical

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that Dr. Wei-Wu He , Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the H.C.Wainwright Bioconnec

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2021 at the 39 th Annual J.P. Morgan Healthcare Conference Announces New Oral HBV RNA Destabilizer, EDP-721, as an Additional Component Toward Functional HBV Cure; Expects to Initiate Phase 1 Study Mid-2021 Expands RSV Program with Introduction of Discovery Initiative for RSV L-Inhibitors

Labcorp (NYSE: LH), a leading global life sciences company, will release its fourth quarter and full year 2020 financial results before the market opens on Thursday, Feb. 11, 2021, and then will host a conference call and webcast beginning at 9:00 a.m. ET to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website . Interested parties

The rising incidence of injuries and bone dislodgement has driven demand within the global femoral prostheses market.

Loop-mediated isothermal amplification (LAMP) have risen in popularity for DNA amplification.

High prevalence of diabetes, overweight, and arthritis has significantly increased the demand for waterproof orthotics.

Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been treated in the global clinical study, RESPOND. The Phase 4 study will examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy Zolgensma

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.

Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative therapies, today announced dosing of the first patient in its biomarker guided Phase 3 clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM)